Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous daratumumab in relapsed or refractory multiple myeloma
MOH_2018-01-17_001913Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab and recombinant human hyaluronidase PH20 in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Started Nov 2017; status: active, not recruiting.
02
Drugs
daratumumabrecombinant human hyaluronidase PH20
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2018-01-17_001913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-17_001913.